Oversight Board Overturns Meta's Decision In Promoting Ketamine For Non-FDA Approved Treatments Case
Portfolio Pulse from Happy Mohamed
The Oversight Board has overturned Meta's decision to allow promotion of Ketamine for non-FDA approved treatments. The board deemed the promotion as a violation of Meta's community standards.
August 17, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Meta's decision to allow promotion of non-FDA approved Ketamine treatments has been overturned by the Oversight Board. This could potentially impact Meta's advertising revenue.
The overturning of Meta's decision could lead to a decrease in advertising revenue if other companies promoting non-FDA approved treatments are also affected. This could negatively impact Meta's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100